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Immune mediated inflammatory anterior segment diseases are variable and their management requires intense
immunosuppression. Treatment with topical steroids is associated with serious ocular side effects. In order to
overcome the potentially blinding complications of topical steroids, immunomodulatory drugs are being used
more frequently. Tacrolimus is a calcineurin inhibitor that induces suppression of T lymphocytes activity and
reduction of ocular inflammation. Tacrolimus was recently investigated for application in various anterior segment
inflammatory disorders. In this review, we will discuss the therapeutic application of topical tacrolimus as a
steroid-sparing agent in treating T cell mediated anterior segment inflammation.
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Background
Immune mediated inflammatory anterior segment diseases
are common and their management requires intense im-
munosuppression. Topical and/or systemic steroids are the
mainstay to control inflammation in these diseases. How-
ever, prolonged use of steroids may lead to development of
serious and sight-threatening complications including cata-
ract, glaucoma and increased susceptibility to infection. In
order to overcome the potentially blinding complications
of topical steroids, immunomodulatory drugs are being
used more frequently.
Tacrolimus was discovered in a soil sample taken from
the foot of Mount Tsukuba in Ibaraki in 1984 [1]. Tacro-
limus, also known as (FK506), is a macrolide produced
from the fermentation broth of a Japanese soil sample that
contained the bacteria Streptomyces tsukubaensis [2]. The
generic name is a neologism composed of “Tsukuba
macrolide immunosuppressive” [3]. It was among the first
macrolide immunosuppressants discovered and was found
to have potent in vitro immunosuppressive effects [1].
The efficacy of tacrolimus as an immunosuppressive agent
was reported in 1986 at the 11th World Congress of the
Transplantation Society in Helsinki, Finland, by re-
searchers from Chiba University, Japan. Within 5 years of
its discovery, clinical trials were initiated for tacrolimus
use in transplant rejection to reduce immune system
activity and to lower the risk of organ rejection following
transplantation [1]. Later on, topical tacrolimus was ap-
proved for the treatment of atopic dermatitis in Japan in
1990, US in 2000 and in Europe in 2001 [4].
Tacrolimus binds to FK506-binding proteins within T
lymphocytes and inhibits calcineurin activity. Calcine-
urin inhibition suppresses dephosphorylation of the nu-
clear factor of activated T cells and its transfer into the
nucleus, which results in the suppressed formation of
cytokines by T lymphocytes [5, 6]. Inhibition of T lym-
phocytes may therefore lead to the inhibition of release
of inflammatory cytokines and decreased stimulation of
other inflammatory cells [6].
Based on the immunosuppressive properties of tacro-
limus, several clinical trials were conducted to assess its
efficacy for ophthalmic use. Different forms and con-
centrations of tacrolimus have been assessed in the
treatment of anterior segment inflammatory disorders
(Tables 1 and 2). Dermatological preparations (Protopic
ointment, Astellas Phama, Tokyo, Japan) were FDA-
approved for the treatment of atopic dermatitis. The
off-label use in a spectrum of variable ophthalmic
conditions has been reported as safe and effective. The
selection of concentration, form and frequency depends
on the disease entity and its severity [7]. The majority
of the previous studies have focused on allergic eye
disease [5]. In the following review, we will discuss the
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applications of topical tacrolimus in various T cell me-
diated ocular diseases.
Review
Topical tacrolimus in allergic eye disease
Th2 lymphocytes play a pivotal role in the pathogenesis
of vernal keratoconjunctivitis (VKC). The levels of Th2-
derived cytokines including mRNA for IL-3, IL-4, IL-5
and IL-13 are increased in patients with VKC [7]. Fur-
thermore, Th2 lymphocytes induce IgE production by
stimulation of B lymphocytes, and lead to activation of
mast cells, eosinophils and neutrophils [7]. In atopic ker-
atoconjunctivitis (AKC) the cell-mediated response is
different from those in VKC. In AKC, there is expression
of both Th1 and Th2 cytokines in the inflamed conjunc-
tiva with potential involvement of Th1-mediated mecha-
nisms [6]. Inhibition of T lymphocytes by tacrolimus may
therefore, lead to inhibition of release of inflammatory cy-
tokines and decreased stimulation of other inflammatory
cells. In addition, the immune-suppressive effects of
tacrolimus are not limited to T lymphocytes, but it may
also act on B cells, neutrophils and mast cells leading to
improvement of symptoms and signs of VKC [8–10].
Different forms and concentrations of tacrolimus have
been assessed in the treatment of allergic eye diseases
including refractory VKC and AKC (Table 1). The main
concentration of topical tacrolimus that was investigated
in the majority of the clinical trials was 0.1% [11–15].
Table 1 Topical tacrolimus in allergic eye diseases
Disease Reference/Authors No. of eyes (patients) Tacrolimus form Frequency Study design
AKC, VKC 11/Ohashi et al. 56 (28) Suspension 0.1% 2 times Prospective
AKC 12/Al-Amri et al. 22 (11) Ointment 0.1% Variable Prospective
AKC, VKC 13/Fukushima et al. 2872 (1436) Suspension 0.1% 2 times Prospective
VKC 14/Vichyanond et al. 20 (10) Ointment 0.1% 1–2 times Prospective
AKC, VKC 15/Miyazaki et al. 1582 (791) Suspension 0.1% 2 times Prospective
VKC 5/Shoughy et al. 124 (62) Solution 0.01% 2 times Retrospective
AKC, VKC 16/Miyazaki et al. 12 (6) Ointment 0.02% 1–4 times Retrospective
VKC 18/Kheirkhah et al. 20 (10) Solution 0.005% 4 times Prospective
VKC = Vernal keratoconjunctivitis; AKC = Atopic keratoconjunctivitis
Table 2 Topical Tacrolimus in anterior segment disorders
Disease Reference/Authors No. of eyes (patients) Tacrolimus form Frequency Study design
CAU 20/Taddio et al. 6 (3) Solution 0.1% 3 times Case series
Scleritis 16/Miyazaki et al. 2 (2) Ointment 0.02% 1–4 times Retrospective
Scleritis 31/Lee et al. 4 (4) Ointment 0.02% 1–4 times Retrospective
GVHD 32/Jung et al. 24 (13) Ointment 0.02% 1–2 times Retrospective
GVHD 33/Tam et al. 2 (1) Ointment 0.03% 2 times Case report
GVHD 34/Ryu et al. 14 (7) Ointment 0.02% 2 times Prospective
GVHD 35/Abud et al. 48 (24) Suspension 0.05% 2 times Prospective
OCP 39/Hall et al. 2 (1) Ointment 0.03% once daily Case report
OCP 40/Michel et al. 2 (1) Ointment 0.03% once daily Case report
OCP 31/Lee et al. 2 (1) Ointment 0.02% 1–3 times Retrospective
SJS 31/Lee et al. 11 (5) Ointment 0.02% 1–3 times Retrospective
SLK 44/Kymionis et al. 4 (2) Ointment0.03% 2 times Case report
AK 47/Ghanem et al. 10 (7) Suspension 0.03% 2 times Prospective
AK 48/Levinger et al. 11 (11) Ointment 0.03% 2 times Prospective
Dry Eye 50/Moscovici et al. 48 (42) Suspension 0.03% 2 times Prospective
PKC 51/Kymionis et al. 2 (2) Ointment 0.03% 2 times Case report
PKP 59/Dhaliwal et al. 4 (4) Ointment 0.03% 2 times Case series
PKP 60/Magalhaes et al. 36 n Suspension 0.03% 2 times Retrospective
PKP 61/Reinhard et al. 20 20) Solution 0.06% 3 times Prospective
CAU = chronic anterior uveitis; GVHD = Graft Versus Host Disease; OCP = Ocular Cicatricial Pemphigoid; SJS = Stevens-Johnson syndrome; SLK = Superior limbic
keratoconjunctivitis; AK = Adenoviral Keratitis; PKC = Phlyctenular keratoconjunctivitis; PKP = Penetrating keratoplasty
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Some other studies evaluated lower concentrations of ta-
crolimus including 0.005, 0.01, 0.02 and 0.03% [5, 16–18].
These studies showed that even with low concentrations
of tacrolimus, the topical eye drop was a safe and effective
treatment modality for patients with VKC refractory to
conventional medications including topical steroids. There
was dramatic improvement of symptoms of itching, red-
ness, photophobia, ocular discomfort, foreign body sensa-
tion and tearing. Similarly, there was improvement of
signs of conjunctival hyperemia, conjunctiva papillae,
limbal infiltration, Trantas’ dots, and superficial punctate
keratopathy. In addition, many patients were well con-
trolled on topical tacrolimus alone without addition of
other medications. However, it was noted that long-term
use of the medication was necessary to control the disease
[18]. Any attempt to discontinue topical tacrolimus during
active disease is associated with immediate recurrence of
symptoms [5].
Topical tacrolimus in anterior uveitis
Uveitis is a sight threatening inflammatory disorder that
affects all ages and remains a significant cause of visual
loss [6, 19]. Uveitis may be idiopathic or associated with
underlying systemic disease. These systemic illnesses
may be infectious or driven by autoimmune mechanisms
[6, 20]. Several forms of uveitis are believed to be medi-
ated by T cells [6].
Since tacrolimus inhibits T-cell proliferation and sup-
presses release of inflammatory cytokines, it can theoretic-
ally be used to reduce inflammatory activity in uveitis
patients [6]. Several studies were conducted to assess the
efficacy of tacrolimus for treatment of immune-mediated
uveitis. The topical form of tacrolimus was initially evalu-
ated in animals [21, 22]. It was found to be effective in
inhibiting endotoxin-induced uveitis and autoimmune uve-
itis in experimental uveitis models [21, 22]. However, tacro-
limus has difficulty penetrating the corneal epithelium and
accumulates in the corneal stroma due to its poor water
solubility and relatively high molecular weight [23]. There
have been several trials aimed at improving corneal
penetration and prolonging precorneal retention time.
Nanoscale drug delivery systems, such as nanoparticles,
cubosomes, nanoemulsions, and liposomes, have shown to
improve corneal penetration and increase retention time
[19, 24]. Intravitreal injection of tacrolimus was similarly
found to be highly effective in suppressing the ongoing
process of endotoxin-induced uveitis in animal studies.
This has led to the assumption that tacrolimus may be use-
ful in the management of patients with uveitis [25].
Based on its success in the treatment of uveitis in animal
models, several trials were conducted to evaluate the effi-
cacy of systemic therapy with tacrolimus in refractory
uveitis [26–28]. Studies that evaluated topical tacrolimus
in humans are scarce. Taddio et al. demonstrated that
topical tacrolimus 0.1% was effective in controlling intra-
ocular inflammation in 3 children with anterior uveitis
with coexistent VKC [20]. The potential role of topical
tacrolimus in treating patients with uveitis is yet to be
determined. Further studies are needed to detect the
optimum concentration and formula of topical tacrolimus.
Topical tacrolimus in scleritis
Normally, the human sclera contains few or no macro-
phages, Langerhans’ cells, neutrophils, or lymphocytes.
After scleral inflammation, there is a marked increase in
T-helper lymphocytes with a highT-helper to T-suppressor
ratio. These findings suggest that T lymphocytes may play
a role in some forms of scleritis [29]. Tacrolimus, being a T
lymphocyte inhibitor, may therefore ameliorate inflamma-
tion in certain forms of scleritis. The use of tacrolimus in
the treatment of scleritis is not well-documented. Young et
al. reported success of systemic tacrolimus in treating
resistant surgically induced necrotizing scleritis [30].
Miyazaki et al. found that topical tacrolimus ointment had
an additive therapeutic effect to topical steroid and helped
to significantly reduce the scleral inflammation in 2
patients with sclerokeratitis [16]. In a study by Lee et al., it
was similarly found that the supplemental use of topical
tacrolimus ointment on the previous systemic and topical
steroid therapy, without adding systemic immunomodula-
tory therapy, could calm active inflammation and help to
taper oral and topical steroid within 3 months in patients
with scleritis [31].
Therefore, topical tacrolimus could be used safely and
effectively to treat certain forms of scleritis particularly
steroid responders and as an adjunctive to systemic
medications. It may also allow the use of a weaker
topical steroid to avoid elevation of IOP or cataract
development. However, it should be emphasized that ex-
treme effort should be taken to diagnose and treat
underlying systemic diseases as tacrolimus may ameliorate
sclera inflammation only leaving the associated systemic
illness poorly managed.
Topical tacrolimus in GVHD
Chronic ocular graft versus host disease (GVHD) occurs
in about 50% of transplant recipients after hematopoietic
stem cell transplantation [32]. The clinical spectrum of
chronic ocular GVHD includes dry eyes and chronic
conjunctival inflammation such as pseudomembranous
and cicatricial conjunctivitis and blepharitis. Although
the pathogenesis of ocular GVHD is still unclear, the in-
flammatory processes of the lacrimal gland and ocular
surface seem to play important roles [32]. Both allo- and
auto-reactive T cells are thought to be involved. Tacroli-
mus is a calcineurin inhibitor and blocks T cell activation
by inhibiting transcription initiation of specific genes [32].
Therefore, tacrolimus may reduce severe ocular surface
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inflammation that results from cell mediated immune
reaction. Tacrolimus is hydrophobic and has a high mo-
lecular weight, which could allow it to permeate the con-
junctiva more than the cornea [22]. The conjunctiva is up
to 20 times more permeable to lipophilic and high-
molecular-weight drugs than is the cornea. This could ex-
plain the higher efficacy of tacrolimus in patients with
ocular GVHD with severe conjunctival inflammation [22].
Hence, topical tacrolimus could be used as an adjunctive
therapy in patients with GVHD to minimize the duration
and dose of topical steroid.
The efficacy of topical tacrolimus for treatment of ocu-
lar GVHD has been reported in few previous studies.
Jung et al. studied 24 eyes of 13 patients with GVHD.
Patients were treated with tacrolimus ointment for up to
20 months [32]. The ocular surface inflammatory score
decreased and the need for steroid treatment also de-
creased after initiating tacrolimus treatment. Tam and
associates demonstrated the efficacy of a 1-month use of
topical 0.03% tacrolimus ointment in controlling initial
inflammation in a single patient with chronic ocular
GVHD [33]. Ryu and associates reported the therapeutic
effect of 0.03% tacrolimus ointment in 14 eyes of 7 pa-
tients with refractory anterior segment inflammatory
disease associated with GVHD [34]. Recently, Abud
et al. found that tacrolimus is a safe and effective thera-
peutic agent for the treatment of ocular manifestations
of GVHD without the known ocular hypertensive effects
of topical steroids [35].
Topical tacrolimus in cicatrizing conjunctivitis
Ocular cicatricial pemphigoid (OCP) is a progressive cica-
trizing conjunctivitis that may lead to fornix foreshortening,
symblepharon formation, trichiasis, dry eye syndrome, cor-
neal scars, ankyloblepharon, and blindness [36]. Evidence
that cicatricial pemphigoid is an autoimmune disease is
considerable [37]. By elaborating cytokines that promote
fibroplasia, the T cells in OCP may be effector cells along
with other types of inflammatory cells in bringing about the
scarring of the conjunctiva. Furthermore, T cells may be re-
sponsible for inducing local B lymphocytes to produce
autoantibodies to the epithelial basement membrane [38].
Experience in treating ocular disease with topical tacroli-
mus has been reported. Hall et al. and Michel et al. re-
ported successful use of topical tacrolimus in the treatment
of patients with OCP [39–41]. Lee et al. evaluated the
therapeutic efficacy of topical tacrolimus in one patient
with OCP and 6 cases of Stevens-Johnson syndrome (SJS).
They found that despite the incomplete effect of topical ta-
crolimus, it contributed to the improvement of epithelial
regeneration, ocular pain, and the progression of symble-
pharon or corneal neovascularization while tapering off
topical steroids [31].
Topical tacrolimus in other ocular surface diseases
Superior limbic keratoconjunctivitis (SLK) is a disease
characterized by inflammation of the upper palpebral
and superior bulbar conjunctiva [42]. Conjunctival speci-
mens from patients with SLK have been shown to have
an alteration in T-cell functions [42, 43].
Given the success of tacrolimus in several T-cell medi-
ated ocular pathologies, it follows that topical tacrolimus
may have utility in the treatment of SLK. Kymionis et al.
reported success of topical treatment in improving ocular
symptoms and controlling surface inflammation with
resolution of superior conjunctiva hyperemia, papillary re-
action and punctate keratopathy in patients with SLK [44].
The subepithelial infiltrates in patients with adenoviral
keratoconjunctivitis represent a cellular immune reac-
tion against viral antigens deposited in the corneal
stroma under the Bowman’s membrane and can persist
for weeks to years [45]. Immune response against viral
replication in subepithelial keratocytes is responsible for
the subepithelial infiltrates [45]. Histologically, these in-
filtrates are composed of lymphocytes, histiocytes, and
antigen-presenting Langerhans cells [46]. Therefore, top-
ical tacrolimus may be considered an effective treatment
regimen. Topical tacrolimus 0.03% was found to be an ef-
fective corticosteroid-sparing agent for the treatment of
patients with symptomatic corneal subepithelial infiltrates
secondary to adenoviral keratoconjunctivitis [47, 48].
The evidence from previous studies suggest that the
ocular inflammation in dry eye disease is mediated by T
lymphocytes. Accordingly, clinical symptoms of dry eye
may be dependent on T-cell activation and subsequent
autoimmune inflammation. Tacrolimus inhibits T lympho-
cyte and suppresses the immune response by inhibiting the
release of other inflammatory cytokines as well (e.g., IL-3,
IL-4, IL-5, IL-8, interferon-gamma, and TNF-alpha). The
reduction in inflammation through inhibition of T-cell ac-
tivation and down-regulation of inflammatory cytokines in
the conjunctiva and lacrimal gland may therefore enhance
tear production [49]. In a prospective double-blind ran-
domized study, topical tacrolimus was found to be effective
in improving tear stability and ocular surface status in
patients with dry eye syndrome [50]. Topical tacrolimus
was also considered in treating severe refractory phlyc-
tenular conjunctivitis and contact lens related papillary
conjunctivitis [51, 52].
Topical tacrolimus following corneal transplantation
Corneal transplantation is a commonly performed oph-
thalmic procedure. Graft rejection still represents a
major threat for the graft. Low-risk grafts have a good
prognosis, with a rejection rate of approximately 13.5%
within 2 years. Topical steroid therapy usually ensures
survival of low-risk corneal grafts [53]. On the other
hand, the reported failure in high-risk grafts rates were
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between 60 and 90% depending on the criteria used to
define high risk. Patients under high risk have been de-
fined as having at least two quadrants of stromal
vascularization and/or a history of previous graft rejec-
tion. Other risk factors include herpes simplex virus
keratitis, chemical burns, large grafts, glaucoma, periph-
eral anterior synechiae, and younger age of the recipient
[53]. Corneal graft rejection is a T cell-mediated immune
response. Therefore, immunosuppressive drugs with T
cell inhibitory action such as tacrolimus could be con-
sidered in the prevention and management of corneal
graft rejection [54]. Several studies have shown en-
hanced graft survival in animal models of high-risk
grafts using topical tacrolimus [55–58].
In humans, topical tacrolimus was evaluated for its ef-
ficacy following keratoplasty especially for high- risk cor-
neal grafts. It demonstrated efficacy in preventing new
episodes of graft rejection [59] and irreversible rejection
[60]. Topical tacrolimus was also evaluated for normal-
risk keratoplasty and was found to provide effective
immunoprophylaxis [61]. Systemic use of tacrolimus was
also evaluated. It may be a safe and effective therapeutic
modality in reducing rejection and prolonging graft sur-
vival in patients with high-risk keratoplasty [53, 62, 63].
Side effects of topical tacrolimus
Topical tacrolimus is generally well tolerated. The most
common side effect is mild and transient ocular irrita-
tion [11]. Burning sensation may occur upon drop instil-
lation but usually does not necessitate discontinuation of
treatment. As an immunosuppressant, topical tacrolimus
use may be associated with increased risk of corneal in-
fections with prolonged use [11]. The incidence of cor-
neal infection in a large cohort of patients treated with
topical tacrolimus was 0.35% [13]. Corneal infections
may be in the form of bacterial keratitis or herpetic cor-
neal ulcer [13]. Accordingly, close monitoring of patients
on prolonged topical tacrolimus therapy is mandatory.
This is particularly necessary in patients with atopic
dermatitis as they are more likely susceptible to herpes
simplex virus infection [11, 13]. Atopic dermatitis pa-
tients treated with tacrolimus skin ointment may also
have an increased risk of T-cell lymphoma [64]. Young
patients with a higher body surface area per weight and
patients with skin abnormalities of the epidermis may
have considerable percutaneous absorption of tacrolimus
ointment. The blood concentrations may be of sufficient
level to induce immunosuppression [64]. Therefore,
caution may be required especially for young patients
with concomitant use of tacrolimus ointment. In such
patients, monitoring the blood level of tacrolimus may
be required [64, 65]. Further studies are needed to detect
if there is a causal relationship between topical applica-
tion of tacrolimus and the development of lymphoma.
Such studies should address the possible risk factors in-
cluding patient age, dose of tacrolimus, blood level of ta-
crolimus following topical use, and underlying systemic
condition. In a study by Ebihara et al., it was demon-
strated that based on the blood concentration profile of
tacrolimus, systemic exposure was minimal and transient
after topical application of the 0.1% ocular preparation
[65]. In fact, the theoretical risk of systemic adverse effects
due to exposure to topical tacrolimus is very low [65].
Conclusion
In conclusion, topical tacrolimus is a promising drug for
treating T cell mediated anterior segment ocular diseases.
More studies are needed to define the optimal formula and
concentration to achieve adequate control of inflammation.
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